Executive Summary

Oct 2019
PROSPECTS
Topical antifungals generate the most sales, being more widely available and less embarrassing to ask for than other dermatological products

Topical antifungals accounted for the highest share of value sales of dermatologicals in 2019 and throughout the review period. Unlike other specific products within dermatologicals, which can only be found in chemists/pharmacies, topical antifungals can easily be found and purchased in drugstores/parapharmacies as well.

Innovations and new product developments boost value growth of antiparasitics/lice treatments

Antiparasitics/lice (head and body) treatments accounted for the second largest share of value sales in 2019 and it is also set to post a strong current value CAGR over the forecast period due to innovations and new product developments such as Laboratorio Roemmers’ launch of a new treatment targeting children in February, accompanied by strong promotion and communication strategies, while hair loss treatments is expected to thrive, driven by continuous innovations and future new releases.

Discomfort with purchasing haemorrhoid treatments and vaginal antifungals is decreasing, but the categories still remain relatively small

Within a society as traditional as Uruguay is, it is not surprising that many people feel uncomfortable about asking for certain intimate products such as haemorrhoid treatments and vaginal antifungals. For this reason many Uruguayans have traditionally postponed or entirely foregone making such purchases at chemists/pharmacists in the hope that the problem will subside without having to visit a pharmacy or the doctor.

COMPETITIVE LANDSCAPE
Laboratorio Roemmers leads in dermatologicals with brands in three categories

Laboratorio Roemmers maintained its leading position in dermatologicals in 2019 on the strength of its brands in several categories. Its vaginal antifungals brand Vitapel and topical antifungal brand Micolis rank second in their respective categories.

Bayer’s Canestan brand leads in dermatologicals on the strength of its position in the large topical antifungal category

Topical antifungals is the largest category within dermatologicals, and the multinational Bayer SA Uruguay continued to dominate value sales in this category in 2019 with its general-purpose brand Canesten. One of the products the company recently discontinued was another topical antifungal, general-purpose Icaden, sales of which were only a fraction of those of Canesten.

Urufarma’s Hipogl?s and Terfin brands in nappy/diaper rash treatments and topical antifungals both see increase value share

Local company Urufarma performed very well in dermatologicals over the review period, with its dominant position of its famous Hipoglós brand within nappy/diaper rash treatments. Moreover, the company’s value share increased in 2019 for the fourth consecutive year.

Want to find out more about this report?
Request more information
Why buy this report?

Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.

Your Recently Viewed Reports

Dermatologicals in Uruguay

Samples (FAQs about samples):

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Medicated Skin Care industry in Uruguay with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Medicated Skin Care industry in Uruguay, our research will save you time and money while empowering you to make informed, profitable decisions.

The Medicated Skin Care in Uruguay market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Medicated Skin Care in Uruguay?
  • What are the major brands in Uruguay?
  • What are the most popular formats for acne treatments?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Dermatologicals in Uruguay - Category analysis

HEADLINES

PROSPECTS

Topical antifungals generate the most sales, being more widely available and less embarrassing to ask for than other dermatological products
Innovations and new product developments boost value growth of antiparasitics/lice treatments
Discomfort with purchasing haemorrhoid treatments and vaginal antifungals is decreasing, but the categories still remain relatively small

COMPETITIVE LANDSCAPE

Laboratorio Roemmers leads in dermatologicals with brands in three categories
Bayer’s Canestan brand leads in dermatologicals on the strength of its position in the large topical antifungal category
Urufarma’s Hipogl?s and Terfin brands in nappy/diaper rash treatments and topical antifungals both see increase value share

CATEGORY DATA

Table 1 Sales of Dermatologicals by Category: Value 2014-2019
Table 2 Sales of Dermatologicals by Category: % Value Growth 2014-2019
Table 3 NBO Company Shares of Dermatologicals: % Value 2015-2019
Table 4 LBN Brand Shares of Dermatologicals: % Value 2016-2019
Table 5 Forecast Sales of Dermatologicals by Category: Value 2019-2024
Table 6 Forecast Sales of Dermatologicals by Category: % Value Growth 2019-2024

Consumer Health in Uruguay - Industry Overview

EXECUTIVE SUMMARY

Improving economy reflected in higher value growth
OTC relatively undeveloped in Uruguay, as health ministry has stricter regulations than in other countries such as neighbouring Argentina
While domestic companies struggle to compete with multinational players, consumer trust and government-backed Mega Pharma support their development
Chemists/pharmacies continues to lose ground to non-store channels and vitamins and dietary specialists
Consumer healthcare is set to see significantly higher growth in most categories over the forecast period

MARKET INDICATORS

Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2014-2019
Table 8 Life Expectancy at Birth 2014-2019

MARKET DATA

Table 9 Sales of Consumer Health by Category: Value 2014-2019
Table 10 Sales of Consumer Health by Category: % Value Growth 2014-2019
Table 11 NBO Company Shares of Consumer Health: % Value 2015-2019
Table 12 LBN Brand Shares of Consumer Health: % Value 2016-2019
Table 13 Distribution of Consumer Health by Format: % Value 2014-2019
Table 14 Distribution of Consumer Health by Format and Category: % Value 2019
Table 15 Forecast Sales of Consumer Health by Category: Value 2019-2024
Table 16 Forecast Sales of Consumer Health by Category: % Value Growth 2019-2024

APPENDIX

OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
Switches

DEFINITIONS

SOURCES

Summary 1 Research Sources